BARCELONA, Spain, May 21 /PRNewswire/ --

- German Medical Device Manufacturer AMG International GmbH announced the submission of its proprietary Itrix Stent Technology using its patented biodegradable drug coating.

Erik Weihenmayer wears sunglasses often. He was wearing them to protect his eyes when he reached the summit of Mount Kilimanjaro in 1997. He had them on when he completed the 2003 Primal Quest, the world's toughest multi-sport adventure race. And, he put on a pair during a recent visit to the National Eye Institute (NEI).

But this last set is no ordinary pair of Oakley sunglasses. 

Weihenmayer looks through them, peering down at a white note card on a table. He silently moves his head back and forth, up and down. After a few moments, he says, "Is that a 12?"

MOSCOW, May 21 /PRNewswire/ --

- Rail network uses IBM hardware and software to manage freight and passenger operations

Russian Railways, one of the largest railway operators in the world, is working with IBM (NYSE: IBM) to help optimize its IT infrastructure and is using new technologies to improve its freight and passenger management systems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO )

SAN JOSE, California, May 21 /PRNewswire/ --

- Gold Level (93%+ efficiency*) 1200-watt Redundant Power Supplies

Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in application-optimized, high-performance server solutions, today announced that its latest generation of enhanced, high-capacity storage chassis with Gold Level certified 1200-watt redundant power supplies are shipping in volume. These chassis feature Supermicro's advanced cooling subsystem designs to deliver optimal system efficiency and TCO by reducing customers' energy bills.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090521/AQ20895)

In 1988, Günter Wächtershäuser published a remarkable idea that excited tremendous interest, even being featured in a Scientific American article. It ran counter to prevailing ideas about the origin of life, and suggested new experimental approaches involving mineral interfaces. Wächtershäuser is a patent lawyer in Munich, Germany who enjoys fabricating intricate and novel approaches to the origin of life, then challenging others to test them. He is greatly influenced by the philosopher Karl Popper, who made the point that explanations are useless unless they are falsifiable.

HOUSTON, Texas, May 21 /PRNewswire/ --

- Using AVEVA PDMS Technology, Company Fast Tracks World's Largest Energy Projects

AVEVA (LSE:AVV) today announced that a major client, Alliance Wood Group Engineering (Alliance) received FIATECH's 2008 Celebration of Engineering Technology Innovation (CETI) Award in the category of Automated Design. The company uses AVEVA's PDMS solution to plan and execute its ultra-deep water exploration projects.

Alliance is part of international energy services company John Wood Group PLC (Wood Group) a provider of engineering, procurement and construction management services for the energy industry.

CAMBRIDGE, Massachusetts, May 21 /PRNewswire/ --

- Specialty Retailer Partners with Allurent for Greater Flexibility, Merchant Control and Customer Engagement

Allurent (http://www.allurent.com/), the market leader in powering superior online shopping experiences, today announced that Charlotte Russe (http://www.charlotterusse.com/)Holding, Inc., a specialty apparel and accessories retailer, will bring interactive merchandising to its e-commerce site with the Allurent on Demand (http://www.allurent.com/) platform. Allurent on Demand (AoD) is a hosted, software-as-a-service (SaaS) offering that increases customer satisfaction and site conversion by quickly and cost-effectively deploying merchant-controlled widgets to retailers' existing websites.

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.

The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida.

The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions:

INDIANAPOLIS, May 21 /PRNewswire/ --

- Both Phase III pivotal trials begin enrollment in May 2009; Reinforces Lilly's commitment to Alzheimer's disease and biotech product research

Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease. The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.